



Figure 2 All signals of Tildrakizumab at the PT level

A-T before PT represents SOC Blood and lymphatic system disorders, Cardiac disorders, Ear and labyrinth disorders, Eye disorders, Gastrointestinal disorders, General disorders and administration site conditions, Hepatobiliary disorders, Immune system disorders, Infections and infestations, Metabolism and nutrition disorders, Musculoskeletal and connective tissue disorders, Neoplasms benign, malignant and unspecified (incl cysts and polyps) , Nervous system disorders, Pregnancy, puerperium and perinatal conditions, Psychiatric disorders, Renal and urinary disorders, Reproductive system and breast disorders, Respiratory, thoracic and mediastinal disorders, Skin and subcutaneous tissue disorders, Vascular disorders respectively.